Comparative Pharmacology
Head-to-head clinical analysis: FURADANTIN versus FURALAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FURADANTIN versus FURALAN.
FURADANTIN vs FURALAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial enzymes involved in cell wall synthesis, DNA replication, and RNA transcription. It is bactericidal against susceptible organisms.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
100 mg orally twice daily for 5-7 days; acute uncomplicated cystitis: 50 mg four times daily or 100 mg twice daily for 5 days.
20 mg orally three times daily for 7 days.
None Documented
None Documented
Terminal elimination half-life is 0.3-1 hour in adults with normal renal function; prolonged to 1-4 hours in renal impairment (creatinine clearance <60 mL/min) and may exceed 20 hours in anuria.
Terminal elimination half-life is 8–12 hours in adults with normal renal function; this supports twice-daily dosing. In patients with creatinine clearance <30 mL/min, half-life may be prolonged to 20–30 hours, requiring dose adjustment.
Renal: 36% (glomerular filtration and tubular secretion); fecal: 40-50% (biliary excretion and unabsorbed drug); hepatic metabolism: minor (acetylation and reduction) accounting for <10%.
Approximately 65–70% of an administered dose is excreted unchanged via renal glomerular filtration and tubular secretion; about 10–15% appears in bile as parent drug or glucuronide conjugate; up to 20% is eliminated in feces via unabsorbed fraction or biliary elimination.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective